- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Outpatient Reimbursement to Increase 65 Percent for EchoGo Heart Failure Platform in 2024
Reimbursement for use of the artificial intelligence (AI)-powered EchoGo Heart Failure platform in hospital outpatient settings for Medicare and Medicaid patients is expected to increase from $99.81 to $284.88 in 2024.
Use of an FDA-cleared artificial intelligence (AI)-enabled system, which reportedly facilitates earlier detection of heart failure with preserved ejection fraction (HFpEF), will generate higher outpatient reimbursement in 2024, according to newly issued coding updates from the Centers for Medicare and Medicaid Services (CMS).
In an update to the ambulatory payment classification (APC) for the Healthcare Common Procedure Coding System (HCPCS) code C9786, the CMS has increased reimbursement from $99.81 to $284.88 for use of the EchoGo Heart Failure system, according to Ultromics, the manufacturer of the platform. The increased reimbursement for the device will go into effect on January 1, 2024.
The EchoGo Heart Failure platform, which received FDA 510(k) clearance in December 2022, reportedly diagnoses HFpEF through analysis of a single echocardiogram view. An August 2023 study noted a 95 percent area under the receiver operating characteristic curve (AUC) in validation testing for HFpEF detection.
“Approximately 50 percent of non-invasive cardiac imaging tests are performed in office-based settings so there is exciting potential for this reimbursement decision to unlock new opportunity to further broaden adoption of our technology,” added Ross Upton, the CEO and founder of Ultromics.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
